The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.

ABSTRACT: Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus pan

SUBMITTER: McNeel DG 

PROVIDER: S-EPMC5170901 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature